Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate Hepatic Artery Injection of Autologous Human Bone Marrow-Derived MSCs in Patients With Alcoholic LC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03838250
Recruitment Status : Not yet recruiting
First Posted : February 12, 2019
Last Update Posted : April 16, 2019
Sponsor:
Information provided by (Responsible Party):
Pharmicell Co., Ltd.

Brief Summary:
This study is to evaluate the safety and efficacy of a single dose of Cellgram™ delivered via hepatic artery in patients with decompensated alcoholic liver cirrhosis.

Condition or disease Intervention/treatment Phase
Alcoholic Liver Cirrhosis Biological: Cellgram™ (Bone marrow-derived MSCs) Phase 1

Detailed Description:

After providing written informed consent, subjects will return to the study center for further evaluation and to have their Bone marrow harvested by an experienced hematologist or interventional radiologist.

Within approximately 1 month (30 ± 7 days) after Bone marrow aspiration, study participants will be admitted to the study center on Day 1.

At the study center, the participant will undergo hepatic artery catheterization by an interventional radiologist who will inject a single dose of Cellgram™. Participants will remain as in-patients and be observed for 24 hours post-infusion. Following discharge, participants will periodically return to the study center for study assessment visits over a period of 1 year.

When a suitable candidate is identified by the Investigator, the Investigator or designated healthcare professional will ask the patient about his/her willingness to be included in the clinical study. Following this, patients will be allowed sufficient time, in their own opinion, to consider study entry, and will be offered the opportunity to ask any further questions prior to signing the informed consent form.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Intervention Model Description: A single-dose injection of autologous bone marrow-derived mesenchymal stem cells (Cellgram™) will be administered to the patient by an experienced interventional radiologist.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open-Label, Single-Dose Study to Evaluate the Safety and Efficacy of Hepatic Artery Injection of Autologous Human Bone Marrow-Derived Mesenchymal Stem Cells (Cellgram™) in Patients With Alcoholic Liver Cirrhosis
Estimated Study Start Date : May 2019
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : June 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cirrhosis

Arm Intervention/treatment
Experimental: Cellgram™ (Bone marrow-derived MSCs)
Infusion Cellgram™(Bone marrow-derived MSCs). Single dose administration of approximately 5 x 10^7 cells/10 mL (range: 4.5 x 10^7 to 5.5 x 10^7 cells/10 mL) via the hepatic artery.
Biological: Cellgram™ (Bone marrow-derived MSCs)
Approximately 15 to 30 mL of bone marrow is aspirated from the posterior iliac crest of patients under local anesthesia. Approximately 30 days (±7 days) after BM aspiration, the participant will return to the study center for admission and for the infusion Cellgram™ (Bone marrow-derived MSCs).




Primary Outcome Measures :
  1. Incidence of Serious Adverse Events [ Time Frame: 12 months ]

    An SAE suggests a significant hazard, contraindication, side-effect, or precaution. With respect to human clinical experience, this includes any event that:

    • Results in death.
    • Is life-threatening.*
    • Requires in-patient hospitalization or prolongation of existing hospitalization.
    • Results in persistent or significant disability/incapacity.
    • Is a congenital anomaly/birth defect.
    • Other medically important condition

      • Life-threatening in the definition of a SAE or adverse reaction refers to an event in which the patient was at risk of death at the time of event; it does not refer to an event, which hypothetically might have caused death if it were more severe.


Secondary Outcome Measures :
  1. Number of patients with Hepatocellular carcinoma (primary liver cancer) development [ Time Frame: 12 months ]
    assessed via ultrasonography and alpha fetoprotein [AFP] analysis

  2. Incidence of Adverse Events [ Time Frame: 12 months ]
    Incidence of Adverse Events as assessed by vital signs, physical examination, safety laboratory tests, and patient reporting

  3. Liver stiffness measurement [ Time Frame: 12 months ]
    with transient elastography (i.e., FibroScan®)

  4. How well the Liver is functioning [ Time Frame: 12 months ]

    by tests including: serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, albumin, gamma glutamyl transpeptidase (GGT) and creatinine.

    Units of Measure: AST will be report in U/L. ALT will be report in U/L. GGT will be report in U/L. Bilirubin will be report in mg/dL. creatinine will be report in mg/dL. Albumin will be report in g/dL


  5. Chronic liver disease as assessed by the Child-Pugh score [ Time Frame: 12 months ]
    The Child-Pugh Score will be used to determine the prognosis, required strength of treatment and the necessity of liver transplantation. The score employs 5 clinical measures of liver disease (total bilirubin, serum albumin, INR, ascites and hepatic encephalopathy). Each parameter is scored 1 to 3, with 3 indicating the most severe derangement.

  6. Model for End-Stage Liver Disease (MELD) Score [ Time Frame: 12 months ]

    MELD uses the patient's values for serum bilirubin, serum creatinine, and the INR for PT to predict survival. It is calculated according to the following formula defined by Kamath et al (2001):

    MELD = 3.78×ln[serum bilirubin (mg/dL)] + 11.2×ln[INR] + 9.57×ln[serum creatinine (mg/dL)] + 6.43


  7. Overall survival [ Time Frame: 12 months ]
    defined as the time from infusion until death from any cause during the study period.

  8. Quality of life as assessed by 36-Item Short Form Survey (SF-36) Questionnaire [ Time Frame: 12 months ]
    The Short Form-36 Quality Of Life questionnaire will be recorded for each patient. The 8 subscales of the SF-36 (Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, Mental Health) and 2 summary component measures (Physical Component Summary, Mental Component Summary) will be calculated and summarized.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Alcoholic liver cirrhosis as diagnosed by clinical, biochemical, radiological, or histological evidence.
  2. Male or female, 18 to 70 years of age, inclusive.
  3. Child-Pugh class B (7 to 9 points)
  4. Capable, in the Investigators opinion, of undergoing hepatic artery catheterization.
  5. No consumption of alcohol or other potentially hepatotoxic substances considered clinically relevant in the opinion of the Investigator, within 6 months prior to screening and throughout the study.
  6. Provision of informed consent by the patient (or their legal representative) to participate in the clinical study.
  7. Able, in the Investigator's opinion, to comply with the requirements of the protocol (including the follow-up period).
  8. Females of childbearing potential must test negative on standard urine pregnancy test and must be willing to practice appropriate contraceptive methods for the duration of the study. Highly effective methods of birth control include hormonal birth control, intrauterine devices (IUDs), or any double-barrier method (sponges, female condoms) used by the woman in addition to contraception used by their male partner such as vasectomy or condom supplemented with spermicide.

Exclusion Criteria:

  1. Current diagnosis of malignant hematologic disease (e.g., acute myeloid leukemia, acute lymphoblastic leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma, multiple myeloma).
  2. Etiology other than alcohol for underlying liver cirrhosis.
  3. Baseline creatinine >1.7 mg/dL and/or estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2
  4. Clinical history of a solid cancer within 5 years prior to screening or current diagnosis of a solid cancer (including hepatocellular carcinoma assessed by ultrasonography and elevated AFP level) and currently receiving cancer treatment.

    Continuous use of a clinically relevant amount of steroids or antibiotics within 1 month prior to screening. Clinical relevance will be determined by the Investigator.

  5. Model for End-Stage Liver Disease score >20.
  6. International normalized ratio >3.0 and/or platelet counts <30,000/mm3
  7. Major operation within 3 months prior to screening.
  8. Presence of extrahepatic biliary stricture.
  9. Participant has undergone transjugular intrahepatic portosystemic shunt.
  10. Active hepatic artery or portal vein thrombosis.
  11. Presence of advanced hepatic encephalopathy Stages 3-4 (West Haven criteria) at the time of screening.
  12. Active variceal bleeding during the last 6 months before screening.
  13. Severe cardiac, renal, or respiratory failure.
  14. Positive serological test results for human immunodeficiency virus (HIV), HCV, hepatitis B surface antigen (HBsAg) and/or syphilis.
  15. Patient is pregnant or breast feeding, or planning to become pregnant while enrolled in the study, up to the EOS visit.
  16. Positive urine pregnancy test at Screening.
  17. Drug abuse within the past 2 years (as confirmed by patient disclosure or a urine drug screen conducted at Screening).
  18. Participation in an interventional clinical study within 30 days prior to screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03838250


Contacts
Layout table for location contacts
Contact: JIYEOUN JEONG, bachelor 82-02-3496-0134 jyjeong@pharmicell.com

Sponsors and Collaborators
Pharmicell Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Juan Gallegos-Orozco, Ph.D University of Utah

Layout table for additonal information
Responsible Party: Pharmicell Co., Ltd.
ClinicalTrials.gov Identifier: NCT03838250     History of Changes
Other Study ID Numbers: PMC-P-08
First Posted: February 12, 2019    Key Record Dates
Last Update Posted: April 16, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Pharmicell Co., Ltd.:
Alcoholic
Liver
Cirrhosis
Liver Disease

Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Cirrhosis
Liver Cirrhosis, Alcoholic
Pathologic Processes
Liver Diseases
Liver Diseases, Alcoholic
Fibrosis
Digestive System Diseases
Alcohol-Induced Disorders
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders